Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmetec Plus combines an ARB with a thiazide diuretic to manage high blood pressure through complementary mechanisms.

• Hypertension: lowers systolic and diastolic blood pressure in patients requiring dual therapy.
• Heart failure prevention: reduces the risk of cardiovascular events in hypertensive patients with additional risk factors.
• Renal protection: helps slow progression of kidney damage associated with long‑term hypertension.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, increasing urinary excretion of water and electrolytes. Together, they reduce peripheral vascular resistance and plasma volume, producing an additive antihypertensive effect.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness: feeling light‑headed, especially after standing quickly.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness or lack of energy.
• Electrolyte imbalance: low potassium or sodium levels.
• Increased urination: due to the diuretic component.
• Mild gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: elevated potassium levels, potentially dangerous.
• Angioedema: swelling of face, lips, tongue, or throat.
• Severe electrolyte disturbances: significant hyponatremia or hypokalemia.
• Allergic reactions: rash, itching, or anaphylaxis.

Before initiating Olmetec Plus, clinicians should assess patient history and monitor relevant parameters.

• Renal function: evaluate creatinine clearance and adjust if impaired.
• Electrolyte levels: check potassium and sodium before and during treatment.
• Volume status: ensure patient is not dehydrated or volume‑depleted.
• Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
• Drug interactions: review concomitant medications for potential additive effects.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmetec Plus may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Aliskiren: combined use in diabetic patients can increase risk of renal impairment.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, risk of hyperkalemia.
• Antidiabetic agents: may enhance hypoglycaemic effect, requiring dose adjustment.